Skip to main content
. 2021 Jun 26;147(11):6337–6348. doi: 10.1007/s10973-021-10929-6

Table 1.

Composition of the lipid nanoparticle formulations used in this research (mass ratio)

DC8,9PC: PEGylated lipid mole ratio Liposomal (LNP) formulation* PEGylated lipid type HPPH encapsulation (20:1 lipid:HPPH)
100:00 DC8,9PC only None No
90:10 DC8,9PC/1 K (10) DSPE-PEG1000 No
99:1 DC8,9PC/2 K (1) DSPE-PEG2000 No
95:5 DC8,9PC/2 K (5) “ No
90:10 DC8,9PC/2 K (10) “ No
80:20 DC8,9PC/2 K (20) “ No
50:50 DC8,9PC/2 K (50) “ No
99:1 DC8,9PC/5 K (1) DSPE-PEG5000 No
90:10 DC8,9PC/5 K (10) “ No
80:20 DC8,9PC/5 K (20) “ No
90:10 DC8,9PC/1 K (10) DSPE-PEG1000 Yes
90:10 DC8,9PC/2 K (10)/HPPH DSPE-PEG2000 Yes
80:20 DC8,9PC/2 K (20)/HPPH DSPE-PEG2000 Yes
90:10 DC8,9PC/5 K (10)/HPPH DSPE-PEG5000 Yes

*The numbers in parentheses indicate the mol% of PEGylated lipid in the liposomal formulations added